AbbVie announced European Commission approval for RINVOQ to treat polyarticular juvenile idiopathic arthritis (pJIA) in children aged two and older. This expands RINVOQ's market reach and adds a new oral solution formulation, reinforcing its position in immune-mediated inflammatory diseases.
AbbVie's RINVOQ has received European Commission approval for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in children aged two and older. This is a positive development as it expands the drug's approved indications, adding to its existing 11 approvals in the EU for various immune-mediated inflammatory diseases. The approval also includes a new oral solution formulation, which could improve patient compliance in the pediatric population. This news is incrementally positive for AbbVie, as it broadens the potential patient base for a key product, contributing to long-term revenue growth and market share in the autoimmune disease space. While not a major catalyst, it reinforces the drug's commercial trajectory and AbbVie's pipeline strength.